Patent Litigation 2024

Last Updated February 15, 2024

Switzerland

Law and Practice

Authors



Pestalozzi is a multicultural Swiss business law firm that has focused on high-end work for domestic and international clients since 1911. Pestalozzi’s lawyers are strong and empathic personalities, known for their truly independent approach to advising and representing their clients. The firm guides and supports its clients in their strategic business decisions, anticipates their future challenges and helps them solve their critical issues. Being fully integrated, Pestalozzi encounters no internal limits in shaping the most competent and efficient teams for clients’ needs. With over 100 professionals in Zurich and Geneva, the firm is at home in Switzerland’s two main commercial hubs. While being locally embedded, Pestalozzi has also developed sought-after expertise in dealing with multi-jurisdictional transactions and disputes. Pestalozzi has a long tradition in providing intellectual property services. Its IP practice group provides results-oriented, effective and pragmatic solutions for the protection and commercialisation of intangible assets, including representing clients from all industry sectors in enforcing and defending their intellectual property rights.

In Switzerland, inventions are primarily protected by patents. A patent with effect for the territory of Switzerland can either be applied for and granted as a Swiss national patent under the Swiss Patents Act (PatA) or as a European patent under the European Patent Convention (EPC) with the designation of Switzerland. According to the PatA and Swiss judicial practice, certain inventions are excluded from patentability, such as gene sequences, methods of medical treatment or mere computer programs.

Under Swiss law, protection of an invention as a utility model is not available and the Federal Council (the Swiss government) recently abandoned its plan to introduce a utility model as part of the partial revision of the PatA that is currently underway.

Undisclosed inventions may qualify as trade secrets and are then protected by law against unlawful use and disclosure, which may qualify as an act of unfair competition (Article 6, Act against Unfair Competition) or a criminal act (Article 162, Penal Code). In addition, trade secrets can be protected through contractual means. The Directive (EU) 2016/943 on the protection of undisclosed know-how and business information (trade secrets) is not directly applicable in Switzerland, which is not an EU country, nor has any analogous law been adopted in Switzerland. Overall, the Swiss provisions on trade secret protection are less detailed than the legal framework in the European Union, but they provide effective protection that meets the requirements of Article 39, paragraph 2 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).

A Swiss national patent is granted pursuant to the PatA upon application to the Swiss Federal Institute of Intellectual Property (Institut Fédéral de la Propriété Intellectuelle, or IPI). European patent applications with protection for Switzerland may be filed with the European Patent Office (EPO) pursuant to the EPC.

European patent applications have the same effect in Switzerland as national patent applications filed with the IPI (Article 110, PatA) and are recorded in the Swiss register once granted by the EPO.

IPI Procedure and “Unexamined” Patents

The IPI currently examines national patent applications only with respect to formal requirements and selected legal requirements, such as the technical nature of the invention, whether the invention is contrary to public policy or morality, the clarity and uniformity of the claims and added matter. In contrast to the examination procedure of European patents by the EPO, the IPI does not examine the material requirements of novelty and non-obviousness before granting the patent (Article 59 paragraph 4, PatA).

As part of the currently ongoing partial revision of the PatA, the Federal Council proposed to keep this “unexamined” national patent, but to also introduce the option to obtain a “fully examined” national patent similar to a patent granted through the European Patent Office. As a result, inventors would have the choice between applying for an “unexamined” or a “fully examined” national patent with the IPI. It is worth noting that the request for full examination may also be filed by third parties, against whom the patent resulting from the application could potentially be held at a later date. In addition, in each case, a public state of the art search report would be prepared, which is intended to give preliminary indications as to the novelty and inventive step of the claimed invention.

Application Procedure

Under the revised PatA, the application documents may also be filed in English, thereby allowing patent applicants to use documents that have been prepared in an international context in the Swiss grant procedure without the need to prepare translations. However, procedural decisions and orders will still be issued in an official language of Switzerland.

Currently, the average costs for the grant of a patent by the IPI amount to approximately EUR700 (without any fees for optional searches). To take a patent application through to the grant stage before the EPO, one may expect costs of around EUR5,000. These costs do not include the fees for the consultancy services of a patent attorney.

Swiss residents do not need to be represented by a patent attorney before the IPI, but applicants (natural or legal persons) who have neither residence nor a place of business in Switzerland are obliged to be represented by a local professional representative. Similar rules apply for residents of non-contracting states in front of the EPO.

Trade secret protection is granted by law, without any examination or registration by any authority, provided that the undisclosed invention meets the conditions for protection, such as confidentiality and an interest in such confidentiality.

Currently, patent examination by the IPI for granting a national patent may last between one and two years or even longer, depending on whether the IPI is asked to provide a report on the state of the art or arrange an international-type search (Article 59 paragraph 5, PatA). Patent granting proceedings by the EPO usually take longer, as the examination of the novelty and obviousness requirements takes time. The European patent grant procedure generally takes about three to five years from the date the application is filed, but in certain cases it can last considerably longer depending on the complexity of the file.

Following the revision of the PatA, the duration of a patent examination is likely to become longer in Switzerland, as the preparation of a state of the art search report by the IPI will be mandatory prior to each patent application and in the case of a full examination, the IPI will also analyse novelty and inventive step.

For both Swiss national patents and European patents with protection for Switzerland, the term of protection is 20 years from the filing date of the patent application (Article 14, PatA).

Inventions that qualify as trade secrets are protected by law as long as the invention meets the conditions for protection – ie, as long as the invention remains confidential and the inventor has an interest in its confidentiality.

Obligations

In order to maintain both Swiss national patents and Swiss parts of European patents, once granted, the patent owner’s primary obligation is to timely pay the registration and annual renewal fees. The amount of the renewal fees is progressive based on the years of protection.

Rights

Both Swiss national patents and European patents with protection for Switzerland, confer on their owners the right to prohibit others from commercially using the invention (Article 8, PatA). It is the responsibility of the patent owner to enforce their exclusivity rights. Possible civil legal actions include:

  • an action for permanent injunction or remedy of the unlawful situation (Article 72, PatA);
  • an action for monetary relief, including damages such as lost profits, accounts of the infringer’s profits and surrender of the unjust enrichment in the form of a reasonable licence fee (Article 73, PatA); and
  • an action for declaratory judgment on the existence or non-existence of a circumstance or right governed by the PatA (Article 74, PatA).

Besides the initiation of civil actions, the patent owner may file a complaint in order to start criminal proceedings against the infringer of their patent rights (Articles 81 et seq, PatA). The PatA also provides for custom measures (Articles 86a et seq, PatA). If the patent owner has clear indications that goods infringing their patent may imminently be imported into or exported out of Swiss customs territory, they may request the Customs Administration to refuse the release of the goods. The Customs Administration may withhold the goods for a maximum period of ten working days, so that the applicant may obtain preliminary measures.

Inventions that are only protected as trade secrets enjoy protection either under Swiss unfair competition law (Article 6, Act against Unfair Competition), under criminal law (Article 162, Penal Code) and/or by contractual means. Unfair competition law provides for civil injunctions, remedies and monetary relief actions as well as for criminal sanctions.

Upon an application by the owner of a Swiss national patent or a European patent with protection for Switzerland, the IPI may grant a supplementary protection certificate (SPC) for the active ingredients or a combination of the active ingredients of medicinal products or plant protection products (Articles 140a et seq, PatA). An SPC can only be granted on the basis of a valid patent and a granted marketing authorisation for the medicinal product.

The period of protection for the SPC begins as soon as patent protection expires and is valid for a maximum period of five years. This term may be extended for a further six months if paediatric studies have been carried out and the results are reflected in the product information of the respective medicinal product (paediatric extension).

For situations where the patent owner is not eligible to apply for an ordinary SPC, which could be prolonged through a paediatric extension, the PatA also provides the possibility of a paediatric SPC that is directly linked to the patent and not to the ordinary SPC.

Third parties currently do not have any right to participate in the grant proceedings for a Swiss national patent or an SPC – eg, by filing third-party observations. However, any person can file an opposition against a Swiss national patent once it is granted by the IPI. Due to the limited scope of the examination by the IPI, national opposition proceedings following grant of Swiss national patents are unattractive. In fact, to date, it appears that the opposition proceedings have never been made use of. The grant of an SPC can be challenged by appeal if the appealing party can show a legal interest in the outcome of the proceedings.

In proceedings before the EPO, third parties can file observations concerning the patentability of the invention (third-party observations) in order to try to prevent a patent from being granted. However, third parties cannot take part in the grant proceedings as a formal party. Any person may, however, file an opposition against a European patent once it is granted by the EPO.

Against a refusal to grant patent protection or an SPC by the IPI, an appeal can be filed with the Swiss Federal Administrative Court and thereafter to the Swiss Federal Supreme Court. Once the partial revision of the PatA enters into force, the Federal Patent Court will be the new appeal instance against administrative grant decisions in patent matters.

A decision of the EPO refusing to grant a European patent may be appealed with the EPO’s Boards of Appeal.

A patent registered in the Swiss patent register is cancelled (and the patent protection terminates with effect ex nunc) if the annual renewal fees are not paid on time.

Where the patent owner provides prima facie evidence of having been prevented, through no fault on their part, from observing a time limit, the IPI may grant, on request, the re-establishment of their rights (Article 47, PatA). Acceptance of the request has the effect of restoring the situation that would have resulted from carrying out the act in good time. However, due to the quite strict practice on the no-fault requirement, Article 47 of the PatA is often not applicable.

Alternatively, the patent owner may file a request for further processing with the IPI (Article 46a, PatA). The request must be made within two months after receiving notification of the missed time limit or within six months after the time limit has expired. Within this time, the action that has been omitted must be executed. If the request for further processing is approved, the situation that would have resulted from executing the act on time will be restored.

Once the patent has been granted (and the opposition period has expired), the patent owner may file a request with the IPI for a declaration of partial surrender of a Swiss national patent or the Swiss part of a European patent in order to:

  • surrender a patent claim;
  • limit an independent claim by combining one or more patent claims, which are dependent on it; or
  • limit an independent claim in some other way – in such cases, the limited claim must refer to the same invention and define an embodiment that is included in the specification of the published patent and in the version of the patent application that determined the date of filing.

The partial surrender may not be used to file new patent claims or to make up for something else that was overlooked in the granting procedure.

On the occasion of registration of a partial surrender, the patent owner may, within a three-month period, file an application for the establishment of one or more new patents to cover the dropped patent claims; such new patents are given the filing date of the original patent.

Under Swiss law, civil legal actions include:

  • actions for permanent injunction or remedy of the unlawful situation (which may also be requested as preliminary measures);
  • actions for monetary relief; and
  • declaratory judgment actions.

Moreover, the patent owner may also initiate criminal proceedings or apply for customs measures.

Please see 1.5 Rights and Obligations of Owners of Intellectual Property Rights for more detail.

Opposition Proceedings

Within nine months of publication, any third party, without the need to demonstrate a proven interest, may file an opposition against a Swiss national patent granted by the IPI or against a European patent granted by the EPO.

Swiss national patents

Grounds for opposition against a Swiss national patent are rather limited. The opposing party may claim that the patent contains inventions that are excluded from patentability because:

  • the invention relates to the human body or its elements;
  • the invention relates to naturally occurring sequences or partial sequences of genes; or
  • the invention’s exploitation is contrary to human dignity or disregards the integrity of living organisms, or is in any other way contrary to public policy or morality according to Article 2 of the PatA.

European patents

The EPC allows for more grounds for opposition. In addition to similar opposition grounds allowed under Swiss law, a third party may also claim that:

  • the invention is not new;
  • the invention does not involve an inventive step;
  • the invention is not susceptible to industrial application;
  • the invention is not disclosed clearly and completely enough for a person skilled in the art to carry it out; or
  • the patent’s subject-matter extends beyond the content of the application as filed.

PatA Revision

After the PatA revision, besides the above-mentioned opposition grounds, the grounds of appeal in national opposition proceedings for fully examined patents will be expanded to include an examination for novelty and inventive step.

Another important reform will be the abolition of the opposition procedure itself. Instead, third parties will be provided with the opportunity to directly appeal grant decisions to the Federal Patent Court. Up until now, the Federal Administrative Court was the appeal instance for all federal administrative matters; eg, opposition decisions of the IPI.

Another novelty foreseen in the draft bill of the PatA revision is the introduction of an organisation’s right to appeal grant decisions in order to take into account diverse public interests and values. According to the draft bill, organisations shall be granted a right to appeal in their own name, provided that they operate on a nationwide basis, pursue purely idealistic purposes, and that the registered patent relates to a field of technology, covered by their statutory purpose for at least five years. The Swiss Parliament is still discussing whether NGOs will be able to invoke the same appeal grounds as other interested parties, or whether their appeal right will remain limited to public policy grounds as it is the case under the current opposition procedure.

Civil Proceedings

Third parties, with a proven interest, may also initiate civil proceedings in order to claim the invalidity or partial invalidity of a Swiss national patent or of the Swiss part of a European patent if the invention is excluded from patentability, is obvious, not novel or not disclosed in a way that a person skilled in the art could carry it out, or if matter was added after the filing date (Articles 26 et seq, PatA).

In addition, when the patent has been filed by an applicant who was not entitled to that patent, the entitled person may apply for assignment of the patent application or, if the patent has already been granted, of the patent itself (Article 29, PatA).

Compulsory Licensing

Under Swiss law, third parties with a legitimate interest may, under certain conditions, also initiate actions for the grant of compulsory licences (Articles 36 et seq, PatA), if:

  • a patented invention cannot be used without infringing a prior patent, provided that the invention represents an important technical advance of considerable economic significance in relation to the invention that is the subject matter of the prior patent;
  • a patent is not sufficiently exploited in Switzerland, and where such a failure to exploit cannot be justified;
  • the public interest so requires;
  • a licence to patents in the field of semiconductor technology is required to remedy a practice held to be anti-competitive; or
  • a licence to use a patented biotechnological invention is required for research purposes.

Requests for the grant of compulsory licences are rare and to date no compulsory licence appears to have ever been granted by a court in Switzerland.

The Swiss Federal Patent Court rules on civil actions concerning patents at first instance. Pursuant to Article 26 of the Patent Court Act (PCA), it has exclusive jurisdiction over civil patent litigation concerning patent validity as well as patent infringement, compulsory licence actions, requests for preliminary measures and enforcement of judgments made under its exclusive jurisdiction.

The Federal Patent Court also has jurisdiction in other civil actions that have a connection to patents, in particular those concerning contractual rights to patents (ownership and licensing) or their assignment. In such cases, the jurisdiction of the Federal Patent Court does not preclude the jurisdiction of the cantonal courts.

An appeal against the decision of the Federal Patent Court or of a cantonal court can only be lodged with the Federal Supreme Court directly as second instance. The decision of the Federal Supreme Court is final. The Federal Supreme Court can, however, remand the case back to the Federal Patent Court for new consideration of certain aspects. In such event, the Federal Patent Court’s second decision can again be appealed to the Federal Supreme Court.

The Federal Patent Court is a specialised court for patent matters. It comprises judges with legal training and judges with a technical qualification.

Besides the Federal Patent Court and cantonal courts, arbitral tribunals may also be competent to resolve disputes related to patents. According to Swiss case law, all aspects of intellectual property disputes are arbitrable, including contractual issues related to patents as well as disputes over the validity of patents. Although arbitral awards on the validity of patents are recognised and enforced in Switzerland, arbitration proceedings related to mere validity disputes are rather rare, because of the multi-jurisdictional nature of most arbitral proceedings and hence possible enforcement issues with respect to certain jurisdictions. However, contractual disputes in connection with patents, such as licensing disputes, are often submitted to arbitral tribunals.

There are no special prerequisites for filing a patent action in Switzerland. Civil actions relating to intellectual property rights can be filed with the competent court without any need to attempt conciliation in front of a conciliation authority.

The issuance of warning letters is also not required, although mostly recommended to consolidate the legitimate interest of the claimant and to support the attribution of the procedural costs to the defendant. Sometimes litigation costs can even be avoided following settlement discussions or voluntary undertakings triggered by warning letters.

If patent infringement proceedings are commenced by an entitled licensee (see 3.1 Necessary Parties to an Action for Infringement), it is not required that the licence is registered in the patent register.

Parties may decide, but do not have any obligation, to be represented by an attorney at law in intellectual property matters. If a party decides to be represented in front of a Swiss court, the representative must be a qualified attorney at law. In proceedings concerning the validity of a patent in front of the Federal Patent Court, the parties may also be represented by a qualified and admitted patent attorney (Article 29, PCA).

Measures for interim relief are available under Swiss law if the applicant can provide prima facie evidence that the following requirements are met:

  • the right to which they are entitled has been infringed or an infringement is imminent;
  • such infringement threatens to cause not easily reparable harm;
  • the requested relief is relatively urgent; and
  • the requested relief is proportionate to the harm caused by the alleged infringement (Articles 261 et seq, Civil Procedure Code, CPC).

Note that urgency is not a strict requirement for granting interim relief. However, interim relief will not be granted if the applicant has waited for a substantial period of time (according to current practice, for more than 14 months) before requesting measures for interim relief.

In cases of special urgency, and in particular where there is a risk that the enforcement of the measure will be frustrated, the court may order the interim measure immediately and without hearing the opposing party (ex parte interim measures) (Article 265, CPC). The ex parte interim measures must subsequently be confirmed in inter partes proceedings granting the opposing party its right to be heard.

In addition, all interim relief proceedings require confirmation in main proceedings. In an interim judgment, the Federal Patent Court will set a deadline for the commencement of main proceedings, whereby the injunction lapses if the applicant does not initiate main proceedings, in which case the applicant is liable for any damages caused to the defendant.

In interim relief proceedings the applicant can, in particular, request:

  • an injunction;
  • an order to remedy an unlawful situation;
  • an order to a registering authority or to a third party; or
  • performance in kind.

Any person who has reason to believe that an ex parte interim measure will be applied against them, may set out their position in advance by filing a protective letter (Article 270, CPC).

Protective letters must be filed with the Federal Patent Court and/or the cantonal courts that are likely to have jurisdiction for ordering the ex parte interim measures in the case at hand. The other party will be served with the protective letter only if they actually initiate the respective ex parte proceedings. The protective letter becomes ineffective six months after it was filed.

Statute of Limitation

Monetary claims in patent infringement proceedings are time-barred after three years from the date on which the injured party became aware of the loss or damage and of the identity of the person liable for them, but in any event ten years after the date on which the loss or damage was caused. If the action for damages is derived from an offence for which criminal law envisages a longer limitation period, that longer period also applies to the civil claim.

Claims for injunctive and declaratory relief are in principle not time-barred, but rather remain available as long as there is a legitimate interest in obtaining such a relief.

Forfeiture

The enforcement of rights might be limited due to their forfeiture based on Article 2 of the Swiss Civil Code, which requires every person to act in good faith in the exercise of their rights. If a person waits too long before initiating enforcement proceedings, their rights may be forfeited if the court determines, taking into account all relevant circumstances, that the claimant acted against good faith. As an example, the right to apply for interim measures is considered forfeited 14 months after the patent owner actually learned, or should have learned, of the infringement unless there are special circumstances (see 2.7 Interim Injunctions). With regard to main proceedings, forfeiture is likely to occur after approximately eight years. Based on Swiss case law, urgent status will not be granted by the courts if the patent owner has waited so long.

Swiss procedural law does not provide any procedural mechanisms for far reaching US-style fishing expeditions in order to obtain all evidence from the opposing party that might be relevant. However, there exist certain mechanisms allowing a party to obtain specific evidence.

PatA

Under the PatA, a patent owner with a legitimate interest – ie, providing prima facie evidence that their patent has been infringed or an infringement is suspected – may request that the Federal Patent Court order as an interim measure:

  • the securing of evidence; and/or
  • a precise description to be made of the allegedly unlawful processes used and/or of the allegedly unlawful products manufactured, as well as the means used to manufacture them (Article 77, PatA).

The procedure for making the description is typically carried out by a technically trained judge and a clerk at the location where the alleged infringement takes place. Upon the request of an opposing party, the court will take necessary measures to safeguard business and trade secrets and might exclude the applicant (but not its representatives) from taking part in the inspection. The court will draft a written report describing the product or process and before the applicant receives the report, the opposing party is given the opportunity to comment (Article 77, PatA).

Under Swiss law there is no limitation as to how the evidence obtained through a description can be used, which means that a Swiss description can also be used to support proceedings abroad.

Swiss Civil Procedure Code

The Swiss Civil Procedure Code also allows a more general right to ensure preliminary taking of evidence without any need to start civil litigation (Article 158, CPC). Similar evidence as during a pending litigation on the merits can be the subject of such a preliminary taking of evidence – ie, the party may request witness hearings, the production of specifically identified documents, the inspection of goods or places or the drafting of a court-appointed expert’s report. The questioning of the parties, however, can only be part of the proceedings on the merits.

In general, the parties to the case, and third parties, have a duty to co-operate in the taking of evidence (Article 160, CPC). However, the court cannot enforce its order, if a party to the proceedings does not produce the required evidence. But the court will take such conduct into account when assessing the evidence and the facts of the dispute.

Under Swiss procedural law, the statement of claim must contain:

  • the prayers for relief;
  • a statement of the value in dispute;
  • the allegations of fact;
  • a notice of the evidence offered for each allegation of fact; and
  • the date and signature.

It is not required by law to state the legal arguments (since the court must know the law), but it is common practice to do so and some courts expressly expect the parties to briefly state on which grounds their actions are based.

In general, in main proceedings, each party is entitled to two submissions during which it may provide new facts and evidence, amend its prayers for relief and limit the patent claims at stake, either inter partes or through a limitation request at the IPI. After the second submission, new facts and new evidence are admissible only if presented immediately after they become known and (i) if they occurred after the second submission (proper nova), or (ii) if they existed before but could not have been submitted despite reasonable diligence (improper nova). At such stage, a limitation of the patent claims at stake will only be considered if it were triggered by new arguments or evidence brought forward in the rejoinder. In any case, new facts and new evidence are admitted only until the court begins its deliberations.

Under Swiss law, no class actions or other collective actions are permitted. However, joinder of parties in civil proceedings is admissible.

Restrictions on the assertion of patent rights may apply from the law against unfair competition and antitrust law, in particular with respect to restrictions against parallel imports which are not justified (Article 9a, PatA and Article 5, Swiss Cartel Act) and unlawful practices by market-dominant undertakings or undertakings with relative market power (Article 7, Swiss Cartel Act).

Furthermore, a patent owner might be restricted in the enforcement of their rights due to their forfeiture based on Article 2 of the Swiss Civil Code (acting in good faith), in particular if they were to wait too long before initiating enforcement proceedings (see 2.9 Special Limitation Provisions).

Civil Actions

A patent owner who has their rights infringed, or is threatened with an infringement, may initiate a civil action. The exclusive licensee, irrespective of the registration of the licence in the patent register, may also bring an infringement action independently, provided this is not expressly excluded by the licence agreement (Article 75, PatA). Non-exclusive licensees, however, may only join the infringement proceedings filed by the patent owner or the exclusive licensee in order to claim their own losses or damages.

An infringement action can be raised against any person:

  • who uses a patented invention unlawfully;
  • who refuses to notify the authority concerned of the origin and quantity of products in their possession which are unlawfully manufactured or placed on the market, and to name the recipients and disclose the extent of any distribution to commercial and industrial customers;
  • who removes the patent mark from products or their packaging without authorisation from the proprietor of the patent or the licensees; and
  • who abets any of the said offences, participates in them, or aids or facilitates the performance of any of these acts (Article 66, PatA).

If there are several infringers, the claimant is not obliged to initiate the infringement action against all potential infringers.

Criminal Proceedings

Criminal proceedings can be initiated against the same persons provided that they wilfully committed the patent infringement, on complaint by the patent owner or ex officio if the infringer acts for commercial gain (Article 81, PatA).

Swiss law does not explicitly know a doctrine distinguishing between direct and indirect patent infringement. Whoever commits an infringement act as described in Article 66 of the PatA may be held liable under Swiss civil and criminal law.

However, the PatA implicitly distinguishes between direct infringement (Article 66 littera a, b and c, PatA) and contributory infringement (Article 66 littera d, PatA), according to which any person who abets, participates in, aids or facilitates the performance of any (direct) infringement may also be held liable under civil and criminal law. According to case law of the Swiss Federal Supreme Court, a contributory infringement is accessory to a direct infringement, meaning that an unlawful principal act is required for a contributor infringement, whereby it is sufficient for a claim for injunctive relief against the contributory infringer that a direct infringement is imminent.

With regard to its application in an international context, the accessoriness has the effect that the contributory infringer acting in Switzerland but contributing to a direct infringement abroad cannot be held liable under Swiss law. On the other hand, if the direct infringement takes place in Switzerland, a contributory infringer contributing to that infringement may be liable irrespective of whether the contributory acts are performed in Switzerland or abroad.

Regarding the supply of (non-infringing) materials or parts to a customer who uses these parts or materials for the manufacture of goods infringing a patent, the Swiss Federal Supreme Court has clarified that the supplier is liable as contributory infringer if they knew or should have known that the means supplied were suitable for, and intended to be used by the customer for use in the infringing goods.

The most important particularity of process patent infringement proceedings concerns the burden of proof. In general, the claimant carries the burden of proof in infringement proceedings. However, the burden of proof may be reversed if the patent in question is a process patent. If an invention concerns a process for the manufacture of a new product, every product of the same composition is presumed to have been made by the patented process until proof to the contrary has been provided (Article 67 paragraph 1, PatA). The same applies by analogy to a process for the manufacture of a known product if the patent owner provides prima facie evidence of an infringement of the patent (Article 67 paragraph 2, PatA).

Regarding the territorial scope of a process patent infringement, the general rules apply, meaning that a direct infringement must occur in Switzerland in order for Swiss law to apply. Accordingly, the Swiss Federal Supreme Court held in a case that if a device intended for carrying out a patented process is manufactured in Switzerland, but the process itself is only carried out abroad, the process patent is not infringed in Switzerland.

Literal Infringements

The patent claims determine the scope of protection of a patent (Article 51 paragraph 2, PatA). According to established practice, the patent claims must be interpreted from the viewpoint of a skilled person, starting with the claim language but also taking into account the description and the drawings. General technical knowledge is also accepted as a means of interpretation.

The Swiss Federal Supreme Court held that the prosecution history of a patent is, in general, not decisive for the interpretation of the patent claims. Waivers and limitations made by the patent applicant during prosecution are to be taken into account only to the extent that they are ultimately reflected in the patent claims and/or the description.

Equivalent Infringements

The PatA explicitly holds that an imitation is also deemed to constitute a use (Article 66 littera a, PatA) and, hence, not only literal infringements but also equivalent infringements are known under Swiss law. The Swiss Federal Supreme Court and the Federal Patent Court have elaborated in several decisions, taking into account other European courts’ practice, a standard test for the assessment of an equivalent infringement based on three main steps.

  • Equal effect – the modified feature must objectively fulfil the same technical function as the corresponding feature of the patent claim.
  • Accessibility – the modified feature must be obvious to the skilled person in light of the teaching of the patent; the Federal Patent Court has clarified that the starting point for the assessment of accessibility is not the general prior art, but the patent at issue, as this step should not be confused with the assessment of the inventive step.
  • Equality – the skilled person must consider the modified feature as an equivalent solution taking into account the claim language and the description.

If all three requirements are fulfilled, an equivalent patent infringement exists according to Swiss practice.

Within Swiss patent infringement proceedings, the defendant may attack the validity of the claimant’s patent or raise non-infringement arguments.

Validity Defences

The defendant may plead the invalidity of the patent as a defence in the form of an objection or as a formal counterclaim. If the defendant raises the invalidity as an objection and the court determines that the patent is in fact invalid, that decision has only a direct effect between the parties – ie, the infringement action is rejected but the patent is not revoked from the patent register. If the defendant decides to file a counterclaim, this has the same effect as a standalone invalidity action – ie, if the invalidity of the patent is confirmed by the court, the infringement action is rejected and the patent is also declared invalid and formally revoked.

Lawful Use Defences

Alternatively, or additionally, defendants may also claim to have lawfully used the allegedly infringed patent. Defendants may argue the following.

  • That they have been granted a valid licence right.
  • That they can rely on a statutory exception as per Article 9 of the PatA, including the exceptions of:
    1. private use for non-commercial purpose;
    2. use for research or experimental purposes (in order to obtain knowledge about the subject-matter of the invention);
    3. use for teaching purposes, use for obtaining marketing authorisation for a medicinal product (Bolar-type exemption);
    4. use by a medicinal professional for an individual person (medical prescription exemption); or
    5. use for a direct individual preparation of a medicinal product in a pharmacy (pharmacists’ exemption).
  • That the patent owner’s rights were exhausted (Article 9a paragraph 1, PatA); whereas in general EEA-wide exhaustion applies, but if the patent is of subordinate importance for the functional characteristics of the goods, global exhaustion applies, and if the price of the patented goods is fixed by the state (such as with medicinal products), national exhaustion applies.
  • That they have a prior use right (ie, have commercially used the invention in good faith in Switzerland or have made special preparations for that purpose prior to the filing or priority date of the patent application (Article 35, PatA)); in this case, the defendant might have to pay the patent owner appropriate compensation (Article 48, PatA).
  • That the patent in question is a standard essential patent and defendants rely on a FRAND (fair, reasonable and non-discriminatory) licence; so far, no case law in this respect has been established in Switzerland since all FRAND cases in front of the Federal Patent Court have been settled.

As a general rule, the Federal Patent Court makes its decisions as a three or five-member body (panel), of whom at least one member must possess technical training. One of the technically trained judges will issue a written opinion (the “Technical Opinion”) covering all technical aspects of the case and the parties are given the opportunity to comment. Such Technical Opinions do not bind the other judges, although in many instances they will be largely followed in the judgment.

Additional technical know-how, at the request of a party or ex officio, may be obtained by an opinion from one or more external experts appointed by the court ad hoc (Article 183, CPC). However, external expert opinions basically do not play a role in patent proceedings, since the Federal Patent Court has technically trained judges with expertise in all relevant fields of science.

The parties may submit written expert statements. However, these are considered as assertions of the parties only.

All arguments against the infringement of patent claims must be raised within the same proceedings. There is no separate procedure for construing patent claims.

Swiss law does not provide for a mechanism in which a third party that is not a party to the patent proceedings could file, on its own, any kind of amicus brief to the court.

There are several reasons for a revocation or cancellation of a patent.

Often, a patent registered in the Swiss patent register is cancelled because the renewal fees are not paid on time.

Swiss national patents or Swiss parts of European patents are also cancelled, and removed from the Swiss patent register, if an action for invalidity of the patent has been successful. The cancellation is done by the IPI upon the provision of full official copies of the final judgments. Any person with a proven interest may bring an invalidity action if the invention is excluded from patentability (eg, human body), is obvious, not novel, not disclosed in a way that a person skilled in the art could carry it out or if the application has been unduly amended (Articles 26 et seq, PatA). The requirements for the interest to be demonstrated by the claimant are rather low. The only exception is an invalidity action based on the allegation that the patent owner has no right to the grant of the patent. This particular ground for invalidity can only be asserted by the person claiming to actually be entitled to the patent.

An action for the cancellation of a patent could also be brought by a person with a demonstrated interest if the grant of licences does not suffice to meet the demand of the domestic market after a period of two years from the grant of the first compulsory licence (Article 38, PatA). Such actions are very rare and to date no patent appears to have ever been cancelled based on such action in Switzerland.

Finally, based on the prohibition against double patenting, a Swiss patent is revoked in favour of a European patent for one and the same invention with effect in Switzerland and granted to the same inventor or to their successor in title with the same filing or priority date (Article 125 paragraph 1, PatA).

Partial cancellation is possible if the successful invalidity action relates to certain patent claims only (Article 27, PatA).

A patent owner may amend a patent by surrendering a patent claim, limiting an independent claim by combining one or more patent claims which are dependent on it or limiting an independent claim in some other way (see 1.10 Post-grant Proceedings Available to Owners of Intellectual Property Rights).

A patent may also be amended during invalidity or infringement proceedings. However, the patent owner is only able to rely on the amended patent up to a certain stage of the proceedings.

The Swiss Federal Supreme Court has clarified that if the patent owner amends the patent through the IPI during pending infringement proceedings, this has an ex tunc effect and thus the original patent that is the subject of the infringement proceedings no longer exists. If the introduction of new facts (ie, the amended patent) is no longer admissible at the stage of the proceedings in question, the infringement proceedings must be dismissed. This is generally the case if the patent is limited after the second pleading, at which stage new facts and new evidence are admissible only under very strict circumstances (see 2.11 Initial Pleading Standards). Hence, if the patent owner wants to proceed against the alleged infringer based on the amended version of the patent, they must commence new infringement proceedings.

Where an invalidity claim is raised as a defence within patent infringement proceedings, that invalidity claim is heard at the same time and within the same proceedings. The Swiss patent litigation system is not bifurcated.

Procedural Provisions

The Swiss Federal Patent Court has exclusive jurisdiction in certain civil patent litigations. However, the proceedings before the Federal Patent Court are primarily based on the ordinary Swiss Civil Procedure Code, which applies to all civil proceedings. The Patent Court Act only contains a few provisions relating to the proceedings (eg, composition of the panel, jurisdiction and legal representatives).

Typical Steps of Infringement Proceedings

Ordinary infringement proceedings are initiated by filing a written statement of claim, followed by a written statement of defence in which the defendant usually asserts invalidity of the patent either by way of a defence or by filing a counterclaim.

After the exchange of the first briefs, the parties are summoned to an instruction hearing in front of a delegation of the court, normally consisting of the court president, the leading technical judge and a court clerk. The instruction hearing consists of two parts. In a first part that is minuted, the court delegation can pose questions to the parties to seek specific clarifications or to get information with respect to parallel proceedings. The delegation will also mention if further substantiation is required. This part is normally quite short. The second, informal part of the instruction hearing is not minuted. The delegation of the court will present a confidential preliminary assessment of the case and the parties may then engage in court-mediated settlement negotiations.

If no settlement is found, the proceedings continue and the parties will exchange their second briefs (ie, reply, rejoinder and comments on new invalidity arguments and evidence in the rejoinder). Thereafter, the technical judge will issue their written expert opinion, on which the parties may comment in writing. As a final step, the parties are summoned to the main hearing. After the parties’ pleadings, the court can decide whether a court expert will be appointed, witnesses will be heard, or other evidence will be taken. In most cases the court closes the proceedings after the main hearing and renders its judgment in writing within four to six weeks.

Ordinary proceedings on the merits concerning infringement or the nullity of a patent generally take about 18 to 24 months.

Action by Stages

An infringement action is typically initiated as a so-called action by stages (Stufenklage). In the first stage, the Federal Patent Court renders a partial judgment on the validity of the patent (if contested), the infringement, injunctive relief and the disclosure of information for the calculation of monetary relief. In the second stage, the patent owner asserts the amount of its monetary relief claim based on the information received and the Federal Patent Court decides on the monetary relief.

The Federal Patent Court makes its decisions as a three-member (or occasionally a five-member) body (panel), of whom at least one member must possess technical training.

In the rare proceedings concerning patent matters that are ruled before civil cantonal courts (see 5.4 Other Court Proceedings), external technical experts may be appointed to submit an expert opinion ex officio or at the request of a party (Article 183, CPC). However, the final decision remains with the judges also with regard to technical questions.

Settlements may be agreed at any stage of civil proceedings. They may be discussed with the mediation of the court or upon separate negotiations among the parties only. Swiss courts often actively support the parties in order to find a settlement.

In front of the Swiss Federal Patent Court, the parties are summoned to an instruction hearing after the exchange of the first briefs (see 5.1 Special Procedural Provisions for Intellectual Property Rights). During this hearing, the court will present a confidential preliminary assessment of the case, which should serve as a basis for settlement discussions. A considerable number of disputes are settled at this stage.

In respect of contractual rights related to patents, such as ownership and licence rights, legal actions may not only be filed with the Federal Patent Court but also with the cantonal courts (Article 26 paragraph 2, PCA). Where the invalidity or infringement of a patent is to be adjudicated in such proceedings as a preliminary question or on a defence basis, the cantonal court grants the parties a reasonable period of time for filing the validity or infringement action before the Federal Patent Court, which has exclusive jurisdiction over this subject matter (see 2.3 Courts With Jurisdiction). The cantonal court must then stay the proceedings until a final decision has been made by the Federal Patent Court. However, considering that actions before cantonal courts with regard to patents have become very rare since the establishment of the Federal Patent Court, the influence of cantonal proceedings on the others are, in practice, very limited.

If infringement proceedings before the Federal Patent Court relate to a European patent which is the subject of pending opposition or appeal proceedings before the EPO, the Federal Patent Court may stay its proceedings. In practice, however, this plays only a very limited role, since the Federal Patent Court emphasises that it only suspends its proceedings if a decision by the EPO can be expected in a short time. Instead, it is the Federal Patent Court’s standard practice to submit an acceleration request to the EPO.

Parallel infringement proceedings in front of other European courts do not have a direct influence on proceedings before the Federal Patent Court. The Federal Patent Court, however, is generally interested in judgments of other European courts when parallel parts of European patents are involved, although such judgments do not bind the Swiss courts in any way.

Anti-suit injunctions of foreign courts are generally considered as inadmissible under Swiss law.

Civil remedies for patent owners include injunctions or reparatory remedies, damages (including legal costs), declaratory judgments, delivery up or destruction of infringing goods, a recall order and publication of the judgment. See 1.5 Rights and Obligations of Owners of Intellectual Property Rights for further detail.

Permanent injunctions are the most common remedy sought in infringement proceedings and are generally granted if an infringement is affirmed. In order to enforce the injunction, the judgment provides for administrative fines (per day of violation) if the infringer does not comply with the injunction, and for criminal sanctions.

For past infringements, the patent owner may claim monetary remedies in the form of damages such as lost profits or, if the infringer acted in bad faith, account of the infringer’s profit. Alternatively, the patent owner can choose to ask for surrender of the unjust enrichment in the form of a reasonable royalty rate. Swiss law does not provide for punitive or exemplary damages or the like.

Since the patent owner usually does not have all the necessary information to prove the amount of damages or the profit to be surrendered, Swiss law grants the patent owner a claim for the necessary information and the infringer may be ordered to render account on the sales and gross turnover made from the infringing activities. Such a claim is usually asserted in a so-called action by stages. See 5.1 Special Procedural Provisions for Intellectual Property Rights.

The court is bound by the available civil remedies and the parties’ prayers for relief and has no discretion in ordering other remedies.

According to Swiss civil procedure law, the losing party must bear the court costs and has to reimburse the prevailing party for its legal costs and expenses, including the costs for assisting patent attorneys. The compensation for legal costs is calculated based on tariffs depending on the value of the dispute. Such compensation will often not cover all the fees actually incurred.

If the defendant has incurred damages as a consequence of the proceedings, they may claim compensation for such damages. Within proceedings for interim measures, the court may make the interim measure conditional on the payment of a security deposit by the applicant, if it is anticipated that the measures may cause damage to the opposing party. An applicant for interim relief is liable for any damages caused in the event such measures are later found to be unjustified. If the applicant proves, however, that they applied for the measures in good faith, the court may reduce the damages or entirely release the applicant from liability (Article 264, CPC).

The same types of remedies are available for infringements relating to Swiss national patents and Swiss parts of European patents. Essentially, also the same types of remedies are available for civil proceedings involving inventions protected as trade secrets. See 1.5 Rights and Obligations of Owners of Intellectual Property Rights for further detail.

An appeal to the Swiss Federal Supreme Court does not have suspensive effect and, accordingly, injunctions granted at first instance are enforceable during the appeal proceedings. Upon request, the Federal Supreme Court may grant suspensive effect, but this is quite rare.

Appeals to the Swiss Federal Supreme Court against decisions of the Federal Patent Court or the civil cantonal courts as sole instance follow the same rules as appeals in civil matters.

The Swiss Federal Supreme Court’s discretion when reviewing final decisions of prior instances on the merits is limited to legal questions. In a recent judgment the Swiss Federal Supreme Court decided that the construction of patent claims is a legal question. In addition, the assessment of invalidity grounds is also a legal question. In contrast, a review of the facts is only possible in a very limited manner by ascertaining an abuse of law by the prior instance in arbitrarily determining the facts (Article 97, Supreme Court Act, SCA).

With regard to decisions on interim measures, the discretion of the Swiss Federal Supreme Court is narrower and limited to a review of a violation of constitutional rights (Article 98, SCA).

Prior to filing a patent lawsuit, there may be significant costs associated with the technical assessment of a patent’s validity (as the defendant’s usual defence will be to bring an invalidity action against the patent) and the assessment of the potential infringement of said patent by the allegedly violating goods of the counterparty. Additional costs may arise for the issuance of warning letters or the preparation and filling of protective briefs.

Court costs are calculated based on tariffs depending on the value of the dispute.

Upon filing an action, the claimant is requested to advance part of the court costs. In proceedings before the Federal Patent Court, the advance payment is usually half of the expected court costs, which corresponds to the expected court costs up to and including the instruction hearing.

As a principle, the losing party must bear the court costs and has to reimburse the prevailing party for its legal costs. A proportionate allocation in relation to the outcome is also possible. Both, court costs and the compensation for legal costs, are calculated based on tariffs depending on the value of the dispute.

In Switzerland, alternative dispute resolution (ADR), or more specifically arbitration, is an important means of resolving intellectual property disputes, particularly in international cases where a single decision is advantageous.

ADR in Switzerland is attractive for patent disputes as Switzerland provides for arbitration experts in most fields of technology and Switzerland has a liberal regime regarding the recognition and enforcement of arbitral awards.

According to Swiss case law, all aspects of intellectual property disputes are arbitrable, including contractual issues related to patents as well as disputes over the validity of patents. Whereas arbitration proceedings related to mere validity disputes are rather rare, contractual disputes are often the subject of arbitration proceedings (see 2.4 Specialised Bodies/Organisations for the Resolution of Disputes).

Under Swiss law, the assignment of intellectual property rights consists of the undertaking to assign the right and the actual disposition of the right. While the undertaking to assign the right is not required to fulfil specific formal requirements, the actual transfer of the patent or patent application rights must be made in writing (Article 33 paragraph 2bis, PatA).

In order to validly assign and transfer the patent or patent application rights neither the approval of the IPI nor its recording in the Swiss patent register is required. However, if the assignment is not recorded, it is invalid against persons who have acquired in good faith rights to the patent from the registered patent owner.

For the recording of the assignment of the patent or patent application rights, the IPI requests the written consent of both the assignor and the assignee.

See 10.1 Requirements or Restrictions for Assignment of Intellectual Property Rights.

Under Swiss law, there are no specific formal requirements for licence agreements. Licence agreements can even be concluded orally and no approval of the IPI is required. However, where the patent application or the patent is owned by two or more persons, a licence grant requires the consent of all co-owners.

Licences may be recorded in the Swiss patent register, but this is not required for their validity between the contractual parties. However, if the licence is not recorded, it is invalid against persons who have acquired the patent in good faith (Article 34 paragraph 4, PatA).

For the recording of the licence rights, the IPI requests the written consent of the licensor.

See 10.3 Requirements or Restrictions to License an Intellectual Property Right.

Pestalozzi

Feldeggstrasse 4
8008 Zurich
Switzerland
Cours de Rive 13
1204 Geneva
Switzerland

+41 44 217 91 11

+41 44 217 92 17

zrh@pestalozzilaw.com www.pestalozzilaw.com
Author Business Card

Trends and Developments


Authors



MLL Legal brings talent, expertise and solution-based teamwork to all IP issues. The members of the IP team rank among the leaders in IP law and have vast experience in Swiss but also in EU and German law. MLL Legal is a leading Swiss patent litigation practice. Boasting excellent and highly knowledgeable advocates, its practitioners work well as part of a multi-jurisdictional team. The firm is highly recommended for patent and other IP disputes and transactions in Switzerland.

Swiss Patent Litigation in 2023

According to statistics, 2023 was a difficult year for patentees in Switzerland.

The Swiss Federal Patent Court published a total of ten judgments in ordinary proceedings. Two of these were nullity proceedings, in which the patents in suit were declared null and void in both cases. Seven judgments were rendered in infringement cases, six of which were dismissed either because the patents in suit were regarded as not infringed or because the patents in suit were held to be invalid. One judgment was an assignment action with a particular setting, which has therefore been excluded from this statistical analysis. Thus, out of nine judgments in ordinary proceedings, eight were decided against the patentee. The statistical likelihood of winning an infringement case in Switzerland was clearly against the patentees. It remains to be seen whether this ratio will continue in 2024.

From the patentee’s perspective, the statistics in summary proceedings are no more encouraging. In 2023, the Swiss Federal Patent Court published eight judgments in summary proceedings. Three judgments concerned assignment proceedings (ie, ownership disputes). One request for a preliminary injunction (PI) was granted, three PI requests due to alleged patent infringement were dismissed, and one application for a “detailed description” was granted. Due to the rather small number of published cases, a significant statistical analysis is not possible, but a certain trend can also be seen here: the Swiss Federal Patent Court applies rather high standards for obtaining a PI in summary proceedings.

In summary, 2023 was a tough year for patentees seeking to enforce their patent rights in Switzerland. However, this general observation may be put into perspective by taking a closer look at the judgments. In particular, the judgments in PI infringement proceedings provide some guidance useful for preparing a global litigation strategy, especially with regard to the question of when to file an action, which is always of great importance in the preparation of patent infringement proceedings. The often conflicting requirements of proving infringement, which generally takes time, thoroughness and diligence, on the one hand, and urgency, which requires quick action, on the other, must always be reconciled.

This article will present three recent cases which have attracted international as well as domestic attention. All three cases deal, among other things, with the question of how to prove patent infringement in an infringement suit and the timing of filing an action.

myStromer v Revolt Zycling (S2023_002, order of 8 June 2023 and judgment of 10 July 2023)

This case concerns the question of what options are available to a patentee in Switzerland when seeking to prove patent infringement without having access to the allegedly infringing product – a problem that often arises when preparing an infringement action in cases where the product cannot be acquired on the market.

The matter relates to a patent dispute between the Swiss bicycle companies myStromer (“Stromer”) and Revolt Zycling (“Revolt”). This dispute has also attracted a great deal of international attention, as parallel to the proceedings in Switzerland, one of the first preliminary injunctions was issued by the UPC based on the evidence that was taken in Switzerland in preliminary taking of evidence proceedings. Stromer then closed Revolt’s booth at EuroBike (Europe’s largest bicycle trade fair) in Germany on 23 June 2023.

But back to the events in Switzerland. Revolt announced on its website that it would offer e-bikes with a specific frame and motor hub design. However, these e-bikes had not yet been available on the market.

In order to obtain access and information about Revolt’s allegedly infringing e-bikes, Stromer filed an application for a “detailed description”, sometimes referred to as “saisie helvétique”.

If there is a risk that the sought evidence could disappear, a detailed description is often ordered ex-parte – ie, without having heard the alleged patent infringer.

The purpose of the “detailed description” is not only to preserve the relevant evidence but it also to allow the patent owner to clarify its chances of success in potential patent litigation. The applicant must demonstrate a legitimate interest in the precautionary taking of evidence. There are no high requirements for the existence of a legitimate interest. However, the applicant must demonstrate that it is not in a position to obtain the evidence through other means. A legitimate interest exists, for example, if the applicant can credibly demonstrate that it is unable to obtain the evidence without running the risk of suffering a substantial disadvantage. Therefore, if a test purchase is only possible at a later date, the time that might be saved due to the “detailed description” may constitute a legitimate interest. A gain in time of only a few weeks is usually, however,  not regarded as sufficient in view of the balance of interests of the patentee and the defendant. If, on the other hand, several months can be gained by the “detailed description”, so that the infringement proceedings initiated with the knowledge acquired by the “detailed description” would already be much further advanced at that time than they could have been if they had been initiated as early as possible without the “detailed description”, the applicant’s interest in accelerating the proceedings prevails.

Stromer’s request for a “detailed description” (ie, an on-site inspection) was based on the alleged infringement of its Swiss part of EP 2 546 134 B1, which protects a combined structure of a frame and a motor hub for an electric bicycle. Stromer argued that the e-bikes in question were not yet available on the market and were not generally available, as each model was unique and tailored to the needs of the individual customer. Therefore, it was not foreseeable for Stromer whether and when it would be possible to make a test purchase after the launch of the e-bikes. The court was convinced that the object of evidence was beyond Stromer’s control, a test purchase was not possible and the evidence could not reasonably be obtained elsewhere.

The Federal Patent Court therefore considered the requested “detailed description” to be necessary in order to protect the applicant’s interests in clarifying the factual and legal situation before infringement proceedings were initiated.

Stromer also credibly argued that the evidence was at risk or that there was an imminent risk of it being thwarted. The assembly of Revolt’s e-bikes took place in the business premises of Revolt. Stromer argued that if Revolt were to learn of the court order for the “detailed description”, there would be a risk that the parts ready for assembly would be taken to another location, possibly even outside Switzerland. According to the court, this was a credible risk. The assembly of a patented combination from individual parts in small batches does not require complex machines that cannot be converted at short notice. Rather, it would be easy to relocate the assembly somewhere abroad.

The “detailed description” was therefore ordered and carried out by the Federal Patent Court immediately and without hearing the defendant due to the risk of thwarting.

The inspection of these bicycles took place on 19 June 2023 at the Swiss headquarters of Revolt.

It takes little imagination to realise that such a request for an on-site inspection is a powerful instrument for the preliminary taking of evidence in Switzerland.

Applicants should note that they bear the costs of the preliminary taking of evidence proceedings. They must advance the court costs of these proceedings, they bear their own attorneys’ fees and patent attorneys’ fees and have also to reimburse the attorneys’ fees and patent attorneys’ fees of the alleged infringer according to the tariff of the Federal Patent Court. If the applicant later conducts successful patent infringement proceedings against the alleged infringer, they can recover these costs. In the Stromer vs. Revolt case, for example, the amount in dispute was set by the court at CHF100,000, which meant that Stromer was ordered to pay court costs of CHF8,000 and party compensation of CHF8,000 to Revolt. 

In the meantime, Stromer has successfully initiated PI proceedings before the UPC based on the information obtained in Switzerland, and Swiss inter partes PI proceedings were also pending when this article was finalised. The hearing in the Swiss PI proceedings took place in December 2023.

Novartis AG against Swissfillon AG (S2022_003, judgment of 3 January 2023)

Novartis AG (“Novartis”) filed a PI application against Swissfillon AG (“Swissfillon”). Swissfillon is a contract manufacturing organisation and a leading company in sterile filling of complex pharmaceuticals. Novartis sought to prohibit the processing and marketing of prefilled syringes of a biosimilar of Lucentis – ie, Ximluci (also known as Xlucane) – from Stada/Xbrane, which is protected by the Swiss parts of Novartis’ EP 3 685 826 and EP 3 777 834.

In parallel, nullity actions were filed against the patents CH/EP 3 685 826 and CH/EP 3 777 834. Opposition proceedings against these two patents filed by multiple opponents were also pending at the European Patent Office.

However, the judgment issued by the Swiss Federal Patent Court neither addresses the validity of the Novartis patents nor clarifies whether Swissfillon’s pre-filled syringes fall within the scope of protection of the patents in suit. Swissfillon defended itself by arguing that it had only carried out acts falling under the Swiss Bolar-type exemption privilege according to Article 9 paragraph 1 littera c of the Swiss Patents Act (PatA). This provision states that the effects of a patent do not extend to acts necessary for obtaining a marketing authorisation for a medicinal product in Switzerland or in countries with equivalent medicinal product control.

Novartis was expected to prove that there is a risk that Swissfillon would commit acts outside the Bolar-type exemption privilege (risk of repeated infringement or risk of first infringement).

Novartis credibly demonstrated that Swissfillon had filled pre-filled syringes with ranibizumab as part of the process validation. However, according to the Federal Patent Court, Novartis had not shown that Swissfillon had already started the commercial production of syringes prefilled with ranibizumab and had carried out acts outside the Bolar-type exemption privilege. Since Swissfillon’s activities had been covered by the Swiss Bolar-type exemption, the Swiss Federal Court stated that there was no risk of repeated infringement.

With regard to a possible risk of first infringement, Swissfillon argued that it had always made clear that, in connection with Xlucane, it only acted within the scope of the marketing authorisation privilege and would only take any further action once the relevant patent situation had been clarified. Swissfillon argued that it had done everything that it was obliged to do and could reasonably do in its position as a contract manufacturer in order to rule out an infringement of patent rights. For this reason, the Court came to the conclusion that there was no threat of first infringement.

Swissfillon also referred to an internal FTO opinion received from Xbrane. The Federal Patent Court stated that relying on an internal FTO opinion would indeed not be sufficient to avert the threat of patent infringement, as Xbrane had an all too obvious interest in downplaying the risk of patent infringement. However, Novartis could not prove that Swissfillon would actually rely exclusively on Xbrane’s internal freedom to operate opinion with respect to the start of the commercial use of Novartis’ products. Taking an overall view of the internal and external correspondence submitted by Swissfillon, the Federal Patent Court found it credible that Swissfillon would take care not to infringe third-party IP rights and would not risk a launch of the ranibizumab products as long as Novartis’ patents were effective.

Another interesting aspect is that Swissfillon apparently refused to sign a cease-and-desist letter obtained from Novartis. However, this did not bother the Federal Patent Court. According to the Federal Patent Court, since neither the risk of repetition nor the risk of first infringement was credibly demonstrated, it could not be concluded from the refusal to sign a cease-and-desist letter that acts of infringement were imminent.

In summary, Novartis’ PI claim was dismissed.

Bayer Intellectual Property GmbH v Acino International AG and Acino Pharma AG (S2023_006, judgment of 25 July 2023)

This case concerns the active ingredient rivaroxaban, sold under the brand name Xarelto. Rivaroxaban is an oral blood thinner that acts as an anticoagulant. It is used to treat deep vein thrombosis and pulmonary embolism.

Bayer Intellectual Property GmbH (“Bayer”) is the registered proprietor of the Swiss SPC C01261606/01, which enjoys a maximum term of protection until 17 June 2024, taking into account the paediatric extension. The SPC protects the use of rivaroxaban as a medicinal product. The basic patent for the Swiss SPC is the Swiss/Lichtenstein part of EP 1 261 606. The validity of the SPC or its basic patent has never been questioned.

Two companies of the Acino (“Acino”) group advertised rivaroxaban on their website as a new product available for out-licensing. Acino’s out-licensing service apparently includes the development and subsequent licensing of an entire drug dossier. In addition to manufacturing and supplying the packaged drug product, Acino also licenses the necessary approvals, authorisations, etc. The out-licensing offer was provided with the following footnote though: “Products subject to patent protection are offered in compliance with applicable patent laws. No sales before the expiration date of valid patents are intended in countries where patents are in force”.

The judgment of the Federal Patent Court states that there is no imminent risk of a market entry of the Acino products. The Federal Patent Court notes that not even the grant of a marketing approval by Swissmedic (the national authorisation and supervisory authority for drugs and medical products in Switzerland) indicates an imminent market entry, as the marketing authorisation only gives the right to market the medicinal product in question, but there is no obligation to do so.

Bayer could not produce specific evidence that potential customers of Acino’s out-licensing programme would not respect Bayer’s Swiss SPC. The Federal Patent Court held that while there is always an abstract risk that a licensee could enter the market before the relevant IP rights expire, this is not sufficient to establish a credible risk of actual infringement.

Accordingly, the President of the Federal Patent Court dismissed Bayer’s application for an ex parte PI due to a lack of credible evidence of non-easily reparable harm.

However, despite this judgment, Acino has removed the rivaroxaban out-licensing offer from its website.

Litigation strategies

A “detailed description” in Switzerland can be a helpful tool for patentees to gather evidence prior to initiating infringement proceedings in Switzerland or abroad. This measure should be taken into account when considering the overall litigation strategy if specific pieces of evidence are still missing for the proof of infringement.

The requirements for proving non-easily reparable harm appear to have become somewhat stricter in Switzerland. While the major part of the legal doctrine and also the materials to the Patent Act do not set high requirements for proving non-easily reparable harm and generally always assume such a disadvantage if an absolute right such as a patent or SPC is infringed, the practice of the Federal Patent Court seems stricter. The fact that an entity markets patent-infringing products and an out-licensing programme and invites potential customers to make contact and prepare the launch of this product does not seem to create sufficient harm to trigger a PI, even if this preparatory work takes place during the term of the patent or SPC.

MLL Legal

Schiffbaustrasse 2
P.O. Box
8031 Zürich
Switzerland

+41 58 552 08 00

+41 58 552 08 01

zurich@mll-legal.com www.mll-legal.com
Author Business Card

Law and Practice

Authors



Pestalozzi is a multicultural Swiss business law firm that has focused on high-end work for domestic and international clients since 1911. Pestalozzi’s lawyers are strong and empathic personalities, known for their truly independent approach to advising and representing their clients. The firm guides and supports its clients in their strategic business decisions, anticipates their future challenges and helps them solve their critical issues. Being fully integrated, Pestalozzi encounters no internal limits in shaping the most competent and efficient teams for clients’ needs. With over 100 professionals in Zurich and Geneva, the firm is at home in Switzerland’s two main commercial hubs. While being locally embedded, Pestalozzi has also developed sought-after expertise in dealing with multi-jurisdictional transactions and disputes. Pestalozzi has a long tradition in providing intellectual property services. Its IP practice group provides results-oriented, effective and pragmatic solutions for the protection and commercialisation of intangible assets, including representing clients from all industry sectors in enforcing and defending their intellectual property rights.

Trends and Developments

Authors



MLL Legal brings talent, expertise and solution-based teamwork to all IP issues. The members of the IP team rank among the leaders in IP law and have vast experience in Swiss but also in EU and German law. MLL Legal is a leading Swiss patent litigation practice. Boasting excellent and highly knowledgeable advocates, its practitioners work well as part of a multi-jurisdictional team. The firm is highly recommended for patent and other IP disputes and transactions in Switzerland.

Compare law and practice by selecting locations and topic(s)

{{searchBoxHeader}}

Select Topic(s)

loading ...
{{topic.title}}

Please select at least one chapter and one topic to use the compare functionality.